Explore key stats, market drivers, and emerging drugsall in one visual!: Click Here
Acne Vulgaris Epidemiological Segmentation
The epidemiological segmentation of Acne Vulgaris in the 7MM from 2020 to 2034 includes:
Total prevalent cases of Acne Vulgaris
Total diagnosed prevalent cases of Acne Vulgaris
Gender-specific diagnosed prevalent cases of Acne Vulgaris
Severity-specific diagnosed prevalent cases of Acne Vulgaris
Treatable cases of Acne Vulgaris
Acne Vulgaris Epidemiology
In 2023, approximately 140.2 million cases of Acne Vulgaris were reported in the 7MM, with the US accounting for roughly 69.5 million cases. These numbers are projected to increase throughout the forecast period.
Females represented 63% of diagnosed Acne Vulgaris cases in the 7MM, indicating a higher prevalence among women.
The severity breakdown of Acne Vulgaris cases in the 7MM is as follows:
Moderate cases comprised the largest proportion, accounting for 45% of diagnosed cases.
Severe cases were the least frequent, constituting only 10% of total cases.
Acne Vulgaris Market
The total market size for Acne Vulgaris in the 7MM was estimated at approximately USD 4.26 billion in 2023.
Acne Vulgaris Market Drivers
The launch of new therapies such as SB204, DMT310, and BTX 1503 is expected to enhance treatment options by offering more targeted, effective, and safer solutions for Acne Vulgaris.
Growing awareness of the condition, particularly its psychological effects, coupled with improved diagnostic capabilities, is anticipated to drive growth in the Acne Vulgaris treatment market.
Acne Vulgaris Market Barriers
The diverse clinical presentations of Acne Vulgaris and variable treatment responses, especially in moderate and severe cases, complicate therapy development and approval, leading to unpredictable treatment outcomes.
High treatment costs, notably for advanced and novel therapies, along with limited healthcare access in some regions, may hinder market growth.
One graphic, all the essentialsclick to explore!: Click Here
Acne Vulgaris Emerging Therapies
SB204
DMT310
BTX 1503
B244
BPX-01
And others
Acne Vulgaris Key Players
Pelthos Therapeutics
Dermata Therapeutics
Botanix Pharmaceuticals
AOBiome LLC
BioPharmX
Timber Pharmaceuticals
And others
Grab your free copy of the infographicessential for any analyst!: Click Here